Dianthus Therapeutics (DNTH) Net Income towards Common Stockholders (2017 - 2025)

Dianthus Therapeutics' Net Income towards Common Stockholders history runs 9 years deep, the most recent figure standing at -$165.2 million for Q3 2025.

• On a quarterly basis, Net Income towards Common Stockholders fell 121.75% year-over-year to -$165.2 million in Q3 2025; TTM through Dec 2025 was -$262.8 million, a 44.5% decrease from a year earlier, with the FY2024 full-year figure at -$266.1 million, down 55.24% from the prior year.
• Net Income towards Common Stockholders retreated to -$165.2 million in Q3 2025 per DNTH's latest filing, from -$50.6 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$7.1 million in Q1 2023 and bottomed at -$165.2 million in Q3 2025.
• The 5-year median for Net Income towards Common Stockholders is -$24.7 million (2021), against an average of -$36.5 million.
• Across the five-year window, Net Income towards Common Stockholders jumped 77.8% in 2023 and sank 453.5% in 2024, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$28.0 million in 2021, then soared by 64.16% to -$10.1 million in 2022, then plunged by 49.89% to -$15.1 million in 2023, then sank by 61.57% to -$24.3 million in 2024, then slumped by 578.43% to -$165.2 million in 2025.
• Per Business Quant, the three latest DNTH Net Income towards Common Stockholders figures stand at -$165.2 million (Q3 2025), -$50.6 million (Q2 2025), and -$47.0 million (Q1 2025).